CAR T-cell therapy for leukemia leads to remissions in clinical trial – Fred Hutch News Service
Fred Hutch News Service |
CAR T-cell therapy for leukemia leads to remissions in clinical trial
Fred Hutch News Service “It was not known whether CAR T-cells could be used to treat these high risk CLL patients,” said lead author Dr. Cameron Turtle, an immunotherapy researcher at Fred Hutch. “Our study shows that CD19 CAR T-cells are a highly promising treatment for CLL … Promising Treatment For Leukemia Leads To Remission In Clinical …IFLScience |
Viet Nam News |
Success of stem cell transplant method
Viet Nam News HCM CITY — The country’s first patient transplanted with his own stem cells, frozen for preservation, to replace stem cells destroyed by chemotherapy or radiation is well on the way to full recovery from non-Hodgkin’s lymphoma, local doctors said … |
Viet Nam News |
Success of stem cell transplant method
Viet Nam News HCM CITY — The country’s first patient transplanted with his own stem cells, frozen for preservation, to replace stem cells destroyed by chemotherapy or radiation is well on the way to full recovery from non-Hodgkin’s lymphoma, local doctors said … |
Thorold News |
Maxim bullish on Abeona, sees 89% upside on prospects of lead gene therapy candidate EB-101; shares up 2%
Seeking Alpha Maxim Group ups its fair value target for Abeona Therapeutics (ABEO +2.2%) to $17 (89% upside) from $14 citing positive prospects for its lead gene therapy candidate, Orphan Drug-tagged EB-101, for the treatment of recessive dystrophic epidermolysis … Maxim Group Just Issued “Buy” Rating on Abeona Therapeutics Inc (ABEO)Highland Mirror Analysts are on the Bearish side about Abeona Therapeutics Inc (NASDAQ:ABEO) this week.WeeklyHub |
|
Oppenheimer Starts Coverage on Editas Medicine, Inc. (EDIT) By Announcing An Initial Rating Of “Perform”
Highlight Press CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cpf1 (CRISPR from Prevotella and Francisella 1), bound to a guide RNA molecule designed to recognize a particular … |
|
Oppenheimer Starts Coverage on Editas Medicine, Inc. (EDIT) By Announcing An Initial Rating Of “Perform”
Highlight Press CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cpf1 (CRISPR from Prevotella and Francisella 1), bound to a guide RNA molecule designed to recognize a particular … |